cgi_dot_animation_long

Products



Our Products

Contextual Genomics offers high quality and cost effective Next-Generation Sequencing (NGS) liquid and tissue biopsy cancer genomic tests optimized for clinical actionability and reimbursement


 


High quality and cost-effective tests.

Contextual Genomics’ cancer genomic tests are best in class clinical grade cancer assays that digitize biologic samples. We develop reimbursable tests that are designed to be inexpensive, medically necessary, allow for rapid scaling, and facilitate the collection of longitudinal patient data by monitoring tumour and blood. Local optimization and validation of the tests occurs within each of our partners facilities. Our cancer genomic tests, suggested operating procedures, and standardized analytics ensures the consistency and quality of the data and derivative clinical reports.


OUR TESTS

FIND IT™

Amplicon Panel Test is designed for next-generation sequencing (NGS) to detect clinically actionable genomic mutations in solid tumor biopsies, including single base substitutions (SNVs), small deletions and insertions of up to 24bp.

FIND IT™ is used to characterize somatic mutations for therapeutic decisions.


FOLLOW IT™

Amplicon Panel Test is designed for next-generation sequencing (NGS) to detect clinically actionable genomic mutations in cell-free circulating tumour DNA (ctDNA) in plasma.

FOLLOW IT™ is ideal for patients when tissue biopsy is not an option or as a time series monitoring tool for progression of cancer and/or to detect treatment resistance.


Our End-to-End Workflow

Short Turnaround Time (TAT) from sample receipt to report generation

We offer a complete End-to-End or “sample-to-report” workflow to our partner labs that guarantees the speed and accuracy of the results. Patients’ privacy is protected as personal information never leaves your local servers.




FIND IT™ : Detecting Mutations in Solid Tumour Tissue

The FIND IT Test focuses on clinically actionable mutations in most solid tumour cancers which are treatable with current therapies or Phase 3 investigational treatments. The results of the assay identify therapeutic targets for patients, acquired drug resistance mutations, and mutations with prognostic and diagnostic implications for patient care. The FIND IT™ Test leads to personalized treatment for patients.

The assay is performed on DNA extracted from formalin-fixed paraffin embedded (FFPE) solid tumour cancers. The results of the assay are presented in a comprehensive report that includes histopathology and interpretation of the sequencing results. Interpretation of the results may include matching of mutations with locally approved drugs, review of recommendations from the National Comprehensive Cancer Network (NCCN), review of the literature, and identification of suitable clinical trials.

FIND IT focuses on more than 146 hotspots and 23 exons in 30 known cancer genes.

GENEPOSITION
AKT1E17
ALKT1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275
ARL702H, S741, W742, V716, H875, F877, T878
BRAFQ201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
CTNNB1D32, S33, G34, S37, T41, S45
DDR2L239, I638, S768
EGFRS492, Exon18, Exon19, Exon20, Exon21
ERBB2G309, S310, L755, C805, Exon20
ESR1K303, S463, V534, P535, L536, Y537, D538
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITExon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
KRASG12, G13, A59, Q61, K117, A146
MAP2K1(MEK1)Q56, K57, K59, D67, C121, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119
METY1253, Exon13, Exon 14 (-50 to +25), Exon18
NRASG12, G13, A59, Q61, K117, A146
PDGFRAN659, R560-E571, D842, L839-Y849
PIK3CAR88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLEExon9, Exon10, Exon11, Exon12, Exon13, Exon14
PTCH1W844, G1093
PTENR130
RETC634, V804, M918
ROS1L2026, G2032
SMOD473, S533, W535
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9

FIND IT TECHNICAL SPECIFICATIONS
Genes30
Hotspots146
Exons23
Turnaround Time (TAT)7 days
Mutation typesSNVs, deletions and insertions(up to 24bp)
Sensitivity>99%
Specificity>99%
Assay CutoffBelow 1% VAF
Mean Depth of Coverage8500x
Assay Reproducibility100%
Sample TypeFFPE blocks, scrolls, cores & unstained slides
Sample RequirementFFPE blocks or unstained slides (5μm sections) with a minimum of 10% tumor cellularity. Scrolls, Cores or DNA must be submitted with representative H&E



FOLLOW IT™ : Detecting Mutations in Plasma

Early Access Version currently available to partners 

The FOLLOW IT Test detects mutations in circulating tumour DNA (ctDNA) derived from plasma. Results from FOLLOW IT™ inform patients and oncologists of treatment response and relapse/remission of disease over time.

FOLLOW IT focuses on more than 146 hotspots and 23 exons in 30 known cancer genes.

GENEPOSITION
AKT1E17
ALKT1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275
ARL702H, S741, W742, V716, H875, F877, T878
BRAFQ201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
CTNNB1D32, S33, G34, S37, T41, S45
DDR2L239, I638, S768
EGFRS492, Exon18, Exon19, Exon20, Exon21
ERBB2G309, S310, L755, C805, Exon20
ESR1K303, S463, V534, P535, L536, Y537, D538
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITExon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
KRASG12, G13, A59, Q61, K117, A146
MAP2K1(MEK1)Q56, K57, K59, D67, C121, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119
METY1253, Exon13, Exon 14 (-50 to +25), Exon18
NRASG12, G13, A59, Q61, K117, A146
PDGFRAN659, R560-E571, D842, L839-Y849
PIK3CAR88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLEExon9, Exon10, Exon11, Exon12, Exon13, Exon14
PTCH1W844, G1093
PTENR130
RETC634, V804, M918
ROS1L2026, G2032
SMOD473, S533, W535
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9

FOLLOW IT TECHNICAL SPECIFICATIONS
Genes30
Hotspots146
Exons23
Turnaround Time (TAT)5 days
Mutation typesSNVs, deletions and insertions (up to 24bp)
Sensitivity>99%
Specificity>99%
Assay CutoffBelow 1% VAF
Mean Depth of Coverage8500x
Assay Reproducibility100%
Sample TypeBlood
Sample Requirement2 x 10 mL of blood in Streck tubes